Cargando…
Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
BACKGROUND: Glucagon-like peptide-1 (GLP-1) is recognized as an important regulator of glucose homeostasis. Efforts to utilize GLP-1 mimetics in the treatment of diabetes have yielded clinical benefits. A major hurdle for an effective oral therapy has been the difficulty of finding a non-peptidic GL...
Autores principales: | He, Min, Su, Haoran, Gao, Weiwei, Johansson, Stina M., Liu, Qing, Wu, Xiaoyan, Liao, Jiayu, Young, Andrew A., Bartfai, Tamas, Wang, Ming-Wei |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997064/ https://www.ncbi.nlm.nih.gov/pubmed/21151924 http://dx.doi.org/10.1371/journal.pone.0014205 |
Ejemplares similares
-
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009) -
Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice
por: Su, Haoran, et al.
Publicado: (2008) -
Laminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion
por: Yang, Liusong, et al.
Publicado: (2017) -
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)